Syphilis Market

Market Overview:

The 7 major syphilis markets reached a value of USD 880.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,493.4 Million by 2035, exhibiting a growth rate (CAGR) of 4.92% during 2025-2035.

The syphilis market has been comprehensively analyzed in IMARC's new report titled "Syphilis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2033". Syphilis is a sexually transmitted disease (STD) due to the bacterium Treponema pallidum that occurs mainly through direct contact with sores of syphilis during sex. The illness goes through four stages: primary, secondary, latent, and tertiary, each with its own symptoms and complications. The initial stage is dominated by painless ulcers or chancres on the site of infection, usually occurring within three weeks of exposure. Without treatment, the infection progresses to the secondary stage, which can manifest as skin rashes, fever, swollen lymph nodes, sore throat, muscle pain, and fatigue. Syphilis becomes latent when not treated, with no visible symptoms but active presence of the bacterium in the body. Tertiary syphilis is the most dangerous form, leading to life-threatening complications such as neurological impairment, cardiovascular problems, and organ damage. Congenital syphilis results when an infected mother passes the disease to her unborn child, resulting in miscarriage, stillbirth, or serious developmental abnormalities. Diagnosis is based on serological tests, such as non-treponemal (RPR, VDRL) for screening and treponemal (FTA-ABS, TPPA) for confirmation. More sophisticated methods such as dark-field microscopy and PCR testing offer direct detection of T. pallidum.

The market for syphilis is growth driven by the increasing incidence of the disease globally, attributed to unsafe sex, multiple sexual partners, and a lack of healthcare in specific areas. Greater awareness drives and increased government support for regular STI screening and early detection are enhancing market growth. The increasing use of point-of-care tests for the diagnosis of syphilis, providing quick and reliable results, is further driving market growth. Also, advances in serological and molecular diagnostic methods, e.g., polymerase chain reaction (PCR) and automated immunoassays, are increasing diagnostic precision and efficiency. The growing prevalence of congenital syphilis has also caused increased activity in maternal screening programs, again fuelling market demand. Further, the availability of enhanced antibiotic therapies, i.e., penicillin substitutes for allergic patients, is growing to offer wider treatment options. The merging of electronic health solutions, including telemedicine for consultation on STIs and mobile-based self-testing kits, is also propelling market growth. In addition, government grants and public health programs to curb the spread of syphilis, especially among high-risk groups, are also set to spur market growth in the next several years.

IMARC Group's new report provides an exhaustive analysis of the syphilis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for syphilis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the syphilis market in any manner.

Recent Developments:

• In January 2024, the U.S. FDA approved the temporary importation of Extencilline, a penicillin-based antibiotic from French manufacturer Laboratoires Delbert, to help address the Bicillin L-A shortage, which is the main treatment for syphilis.
• In July 2023, the World Health Organization introduced updated guidelines aimed at improving syphilis testing and diagnosis. These guidelines focus on expanding access to cost-effective point-of-care diagnostic tests to enable early detection and timely treatment.
• In September 2023, the National Institutes of Health allocated USD 2.4 million to enhance syphilis testing in the U.S. This initiative is focused on developing more efficient and accurate diagnostic tools to better address the increasing prevalence of the disease.

Key Highlights:

• In 2022, global syphilis cases reached 8.0 million among adults aged 15–49, rising from 7.1 million in 2020.
• The EU/EEA reported 41,051 syphilis cases in 2023, a 13% increase from 2022 and a 100% rise since 2014.
• In Europe, syphilis incidence was seven times higher in men, peaking at 43 cases per 100,000 among men aged 25–34 in 2023.
• In 2022, congenital syphilis caused 390,000 adverse birth outcomes worldwide, including 150,000 fetal deaths, 70,000 neonatal deaths, and severe complications in newborns.
• In 2023, U.S. infectious syphilis cases declined by 10%, but late-stage and congenital syphilis cases continued to rise, posing ongoing public health concerns.

Drugs:

Pfizer's Benzathine Penicillin G is an intramuscular antibiotic designed for syphilis treatment, targeting Treponema pallidum. It halts disease progression by eliminating the bacteria. Potential side effects include allergic reactions and injection site pain. This long-acting formulation ensures sustained bacterial suppression, making it a key therapy for syphilis management.

Doxycycline, a tetracycline-class antibiotic from Pfizer, is used to treat syphilis by inhibiting bacterial protein synthesis. The standard regimen involves 100 mg orally twice daily for 14 days in early-stage syphilis and 28 days in late-stage cases. Potential side effects include nausea, diarrhea, and photosensitivity.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the syphilis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the syphilis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current syphilis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the syphilis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the syphilis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the syphilis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of syphilis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of syphilis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035​) of syphilis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with syphilis across the seven major markets?
• What is the size of the syphilis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of syphilis?
• What will be the growth rate of patients across the seven major markets?

Syphilis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for syphilis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the syphilis market?
• What are the key regulatory events related to the syphilis market?
• What is the structure of clinical trial landscape by status related to the syphilis market?
• What is the structure of clinical trial landscape by phase related to the syphilis market?
• What is the structure of clinical trial landscape by route of administration related to the syphilis market?